ArticleFrontiers in public health2025
Comparative models on low multiplier DRG classification for advanced lung cancer.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to compare the performance of machine learning models in predicting low multiplier DRGs for advanced lung cancer, and to identify the optimal algorithm along with key influencing factors. Methods: Prediction models for low multiplier DRGs in advanced lung cancer were developed using four machine learning algorithms: logistic regression, hybrid naive Bayes, support vector machine (SVM), and random forest. Model performance was evaluated, and key contributing features were identified. Results: The random forest algorithm achieved the highest AUC, accuracy, and precision across all three ER group, indicating robust performance. Second, cost-related features and length of hospital stay (LoS) reflecting "resource consumption" contributed significantly more to the low multiplier DRGs prediction than demographic factors such as gender and age. Conclusion: Based on comorbidity severity, the DRG classification for advanced lung cancer patients receiving internal medicine treatment under ER1 appeared reasonably structured and provided a valid basis for subgroup comparisons. Additionally, according to the predictive model's findings, potential signs of upcoding and intentional underuse of reimbursable medications were observed, highlighting the need to monitor examination fee reductions across ER1 subgroups and to track medication costs in ER11 throughout the hospital stay. Lastly, in predicting low multiplier DRGs, larger datasets improve model stability. Model choice should align with the analytical goal: Random Forest offers higher precision and robustness, while logistic regression or SVM may be preferred for higher recall.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.